76907 - Rethinking anti-coagulation in non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE)
- : Online
Accredited Active Learning Module - on-line education program for GPs to help them better prevent coagulation in patients with AF and VTE.
Rethinking anti-coagulation in non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE)
The prevalence of atrial fibrillation in Australia is around 1 to 2%. In 2008 there were an estimated 14,716 cases of venous thromboembolism (VTE) in Australia (56% pulmonary embolism (PE) and 44% deep vein thrombosis (DVT). Classical clinical symptoms of AF include palpitations, lack of energy, dizziness, chest discomfort and dyspnoea, but about 30% of patients with AF may be asymptomatic and unaware of the arrhythmia, and ischaemic stroke may be the first manifestation. AF is associated with a five-fold increase in stroke risk and AF associated ischaemic strokes are often fatal.
Clinical guidelines state that all patients with NVAF and one additional risk factor for stroke and without contraindications, should be treated with long-term anticoagulation, because of good evidence that this reduces stroke and systemic embolism risk.